Skip to main content
Sinco Pharmaceuticals Holdings Limited logo

Sinco Pharmaceuticals Holdings Limited — Investor Relations & Filings

Ticker · 6833 ISIN · KYG8154Y1052 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,670 across all filing types
Latest filing 2026-05-22 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 6833

About Sinco Pharmaceuticals Holdings Limited

http://www.sinco-pharm.com

Sinco Pharmaceuticals Holdings Limited is an investment holding company specializing in the provision of comprehensive Marketing, Promotion, and Channel Management (MPCM) services within the biopharmaceutical industry. The company strategically focuses on three core business segments: biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. Sinco offers integrated, full life-cycle solutions, primarily serving overseas pharmaceutical manufacturers seeking market entry and distribution in the PRC. A significant activity includes acting as the exclusive authorized agent across 31 provinces for Octapharma, a leading global blood product manufacturer, distributing key products such as Human Albumin. The company's service portfolio encompasses both pharmaceutical products and medical devices.

Recent filings

Filing Released Lang Actions
APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHAIRMAN OF THE NOMINATION COMMITTEE
Board/Management Information Classification · 95% confidence The document is an announcement on HKEX of the appointment of Mr. Huang Zhijian as Chairman of the Board and Chairman of the Nomination Committee. It details changes in the company’s board composition and does not include any financial statements or report attachments. This falls squarely under Board/Management Information (MANG).
2026-05-22 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 85% confidence The document is a public announcement detailing the composition of the board of directors and their committee roles for Sinco Pharmaceuticals. It sets out executive, non-executive, and independent non-executive directors and committee memberships, which aligns with a Board/Management Information disclosure. There is no substantive financial data or voting results; it is purely governance information regarding board roles.
2026-05-22 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 15 MAY 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement of the poll results from the Annual General Meeting of Sinco Pharmaceuticals held on 15 May 2026. It lists the resolutions proposed, vote counts for and against each resolution, and confirms all resolutions were passed. This aligns exactly with the definition of a Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 100% confidence The document is a monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Sinco Pharmaceuticals Holdings Limited. It details movements in authorized share capital, issued shares, treasury shares, share options, and public float sufficiency confirmation. The document is a regulatory submission reporting share capital and shareholding changes for a specific month (April 2026). It does not contain financial statements, earnings data, management discussion, or audit information. It is not an announcement of a report but a regulatory filing of share capital movements and confirmations pursuant to HKEX listing rules. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-06 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors and their roles and functions, including committee memberships. It does not contain financial data, earnings, or detailed management discussion. It is focused on governance structure and board composition. The document length is short (1267 characters), and it is a straightforward announcement of board members and their committee roles. This fits the definition of Board/Management Information (MANG), which covers announcements of changes or details about the company's board of directors or senior management.
2026-04-30 English
(1) RESIGNATION OF CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR, CHAIRMAN OF NOMINATION COMMITTEE AND AUTHORISED REPRESENTATIVE; (2) CHANGE OF AUTHORISED REPRESENTATIVE; AND (3) NON-COMPLIANCE WITH RULE
Board/Management Information Classification · 100% confidence The document is an announcement from Sinco Pharmaceuticals Holdings Limited regarding the resignation of the chairman of the board and other related changes in board positions. It also discusses non-compliance with a listing rule and the appointment of a new authorised representative. There is no financial data, no report attached or referenced as being published, and the content focuses solely on board and management changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is clearly an announcement, not a full report or financial statement.
2026-04-30 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.